| 10.06 -0.23 (-2.24%) | 07-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.18 |
1-year : | 13.03 |
| Resists | First : | 10.43 |
Second : | 11.15 |
| Pivot price | 9.84  |
|||
| Supports | First : | 9.25 |
Second : | 7.69 |
| MAs | MA(5) : | 10.23 |
MA(20) : | 9.81 |
| MA(100) : | 8.04 |
MA(250) : | 6.89 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 60.3 |
D(3) : | 73.8 |
| RSI | RSI(14): 52.2 |
|||
| 52-week | High : | 11.15 | Low : | 4.51 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ICCC ] has closed below upper band by 45.4%. Bollinger Bands are 18.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.46 - 10.52 | 10.52 - 10.57 |
| Low: | 9.78 - 9.85 | 9.85 - 9.91 |
| Close: | 9.82 - 9.92 | 9.92 - 10.01 |
ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves. The company also provides Tri-Shield First Defense, a passive antibody treatment effective against E. coli, coronavirus, and rotavirus. Additionally, ImmuCell offers the California Mastitis Test, a diagnostic instrument used to quantify somatic cell counts in milk and identify which specific udder quarter may be affected by mastitis. Its Dual-Force First Defense product, incorporating a whey protein concentrate, caters to the nutritional and animal feed supplement industries. Currently under development is Re-Tain, a Nisin-based intramammary therapy targeting subclinical mastitis in lactating dairy cows. The company primarily distributes its products through a network of animal health distributors. ImmuCell Corporation was established in 1982 and is based in Portland, Maine.
Thu, 02 Jul 2026
(ICCC) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Thu, 02 Jul 2026
Price to sales forward of ImmuCell Corporation – NASDAQ:ICCC - TradingView
Wed, 01 Jul 2026
ImmuCell Corporation (ICCC) Gains 1.39% as Stock Approaches Key Resistance at $10.70 - Inverse ETF Flow - dars.gov.et
Mon, 22 Jun 2026
ImmuCell (ICCC) CEO increases stake with 8,000-share open-market buy - Stock Titan
Sun, 21 Jun 2026
Responsive Playbooks and the ICCC Inflection - Stock Traders Daily
Thu, 18 Jun 2026
ICCC's Valuation Remains Premium: Is it Worth Overpaying for? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 9 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 32.1 (%) |
| Held by Institutions | 21.7 (%) |
| Shares Short | 12 (K) |
| Shares Short P.Month | 10 (K) |
| EPS | -0.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.22 |
| Profit Margin | -1.9 % |
| Operating Margin | 19 % |
| Return on Assets (ttm) | 4.5 % |
| Return on Equity (ttm) | -1.9 % |
| Qtrly Rev. Growth | 28.3 % |
| Gross Profit (p.s.) | 1.4 |
| Sales Per Share | 3.3 |
| EBITDA (p.s.) | 0.64 |
| Qtrly Earnings Growth | 31.2 % |
| Operating Cash Flow | 4 (M) |
| Levered Free Cash Flow | 3 (M) |
| PE Ratio | -141.72 |
| PEG Ratio | 0 |
| Price to Book value | 3.08 |
| Price to Sales | 2.99 |
| Price to Cash Flow | 20.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|